Skip to main content
Top
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line

Authors: Jing Zhang, Dongmei Wang, Na Hu, Qian Wang, Shanice Yu, Jun Wang

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

This study aims to design and generate recombinant lentiviral vector containing the complete coding sequence (CDS) region of human serine protease inhibitor Kazal type 1 gene (SPINK1) and establish a human pancreatic cancer cell line (AsPC-1) stably overexpressing SPINK1. Then, to assess the proliferative and oncogenic effects of upregulated SPINK1 gene on pancreatic cancer AsPC-1 cells using different methods. Initially, the target coding sequence (CDS) of SPINK1 was amplified by polymerase chain reaction (PCR) and the synthesized product was subsequently subcloned into the lentiviral vector. The construction of recombinant SPINK1 gene was verified by the restriction digestion and sequencing analysis. The lentiviral particles carrying SPINK1 gene were produced by co-transfection of the recombination lentiviral vector and the packaging mix plasmids into 293 T cells and filtered and concentrated before AsPC-1 cells were infected by the virus particles. The cells transduced were differentially selected with puromycin, and the clones that highly expressed SPINK1 were chosen by real-time PCR and confirmed by Western blot after 7 weeks. The stably transduced AsPC-1 cell line showed significantly increased metabolic and proliferative capability using CCK-8 and Trypan Blue assays (P < 0.001). Cell cycle and DNA content analysis by flow cytometry showed that upregulated SPINK1 elicited significant increase in the percentage of AsPC-1 cells in the S and G2/M phase (P < 0.001). Clone formation assay demonstrated that the number of the colonies formed in the experimental group was greater than that in the control parental cells (P < 0.001). It was concluded that a stable AsPC-1 cell line capable of overexpressing SPINK1 had been successfully created, and that the proliferative capacity of AsPC-1 pancreatic cancer cells was significantly raised by SPINK1 upregulation as well as the ability of a single AsPC-1 cell to grow into a colony.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yutong H et al. Pancreatic cancer incidence and mortality patterns in China, 2011. Chin J Cancer Res. 2015;27(1):29–37. Yutong H et al. Pancreatic cancer incidence and mortality patterns in China, 2011. Chin J Cancer Res. 2015;27(1):29–37.
2.
go back to reference Kozak G, Blanco FF, Brody JR. Novel targets in pancreatic cancer research. Semin Oncol. 2015;42(1):177–87.CrossRefPubMed Kozak G, Blanco FF, Brody JR. Novel targets in pancreatic cancer research. Semin Oncol. 2015;42(1):177–87.CrossRefPubMed
3.
go back to reference Ida S et al. SPINK1 status in colorectal cancer, impact on proliferation, and role in colitis-associated cancer. Mol Cancer Res. 2015;13(7):1130–8.CrossRefPubMed Ida S et al. SPINK1 status in colorectal cancer, impact on proliferation, and role in colitis-associated cancer. Mol Cancer Res. 2015;13(7):1130–8.CrossRefPubMed
4.
go back to reference Ogata N. Demonstration of pancreatic secretory trypsin inhibitor in serum-free culture medium conditioned by the human pancreatic carcinoma cell line CAPAN-1. J Biol Chem. 1988;263(26):13427–31.PubMed Ogata N. Demonstration of pancreatic secretory trypsin inhibitor in serum-free culture medium conditioned by the human pancreatic carcinoma cell line CAPAN-1. J Biol Chem. 1988;263(26):13427–31.PubMed
5.
go back to reference Nobuyuki O et al. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Sci. 2013;20(6):620–7.CrossRef Nobuyuki O et al. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Sci. 2013;20(6):620–7.CrossRef
6.
go back to reference Marchbank T, Mahmood A, Playford RJ. Pancreatic secretory. Trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. Am J Physiol Renal Physiol. 2013;305(3):382–9.CrossRef Marchbank T, Mahmood A, Playford RJ. Pancreatic secretory. Trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. Am J Physiol Renal Physiol. 2013;305(3):382–9.CrossRef
7.
go back to reference Ohmachi Y et al. Overexpression of pancreatic secretory trypsin inhibitor in pancreatic cancer. Evaluation of its biological function as a growth factor. Int J Pancreatol. 1994;15(1):65–73.PubMed Ohmachi Y et al. Overexpression of pancreatic secretory trypsin inhibitor in pancreatic cancer. Evaluation of its biological function as a growth factor. Int J Pancreatol. 1994;15(1):65–73.PubMed
8.
go back to reference Ohmuraya M, Yamamura K. The roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. J Exp Anim. 2011;60(5):433–44.CrossRef Ohmuraya M, Yamamura K. The roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. J Exp Anim. 2011;60(5):433–44.CrossRef
9.
go back to reference Ozaki N et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res. 2009;7(9):1572–81.CrossRefPubMed Ozaki N et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res. 2009;7(9):1572–81.CrossRefPubMed
10.
go back to reference López-Sáez JF et al. Cell proliferation and cancer. Histol Histopathol. 1998;13(14):1197–214.PubMed López-Sáez JF et al. Cell proliferation and cancer. Histol Histopathol. 1998;13(14):1197–214.PubMed
12.
go back to reference Taylor HE et al. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol. 2014;1:592–603.CrossRef Taylor HE et al. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol. 2014;1:592–603.CrossRef
13.
go back to reference Shearer RF, Saunders DN. Experimental design for stable genetic manipulation in mammalian cell lines: lentivirus and alternatives. Genes Cells. 2015;20(1):1–10.CrossRefPubMed Shearer RF, Saunders DN. Experimental design for stable genetic manipulation in mammalian cell lines: lentivirus and alternatives. Genes Cells. 2015;20(1):1–10.CrossRefPubMed
14.
go back to reference Chen Y et al. Construction and application of a lentiviral vector of single-chain variable fragment antibody against human hepatocyte growth factor receptor. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014;30(9):960–3. Chinese.PubMed Chen Y et al. Construction and application of a lentiviral vector of single-chain variable fragment antibody against human hepatocyte growth factor receptor. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014;30(9):960–3. Chinese.PubMed
15.
go back to reference Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther. 2015;15(3):337–51.CrossRefPubMed Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther. 2015;15(3):337–51.CrossRefPubMed
16.
go back to reference Tominaga H et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun. 1999;36:47–50.CrossRef Tominaga H et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun. 1999;36:47–50.CrossRef
17.
go back to reference Spyratos F et al. Biology of the cell DNA content and cell cycle analysis by flow cytometry in clinical samples: application in breast cancer. Biol Cell. 1993;78(1–2):69–72.CrossRefPubMed Spyratos F et al. Biology of the cell DNA content and cell cycle analysis by flow cytometry in clinical samples: application in breast cancer. Biol Cell. 1993;78(1–2):69–72.CrossRefPubMed
18.
go back to reference Favoni RE, de Cupis A. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev. 2000;52(2):179–206.PubMed Favoni RE, de Cupis A. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev. 2000;52(2):179–206.PubMed
19.
go back to reference Wood CE et al. Scientific and regulatory policy committee (SRPC) review: interpretation and use of cell proliferation data in cancer risk assessment. Toxicol Pathol. 2015;43(6):760–75.CrossRefPubMed Wood CE et al. Scientific and regulatory policy committee (SRPC) review: interpretation and use of cell proliferation data in cancer risk assessment. Toxicol Pathol. 2015;43(6):760–75.CrossRefPubMed
20.
21.
go back to reference Niinobu T et al. Identification and characterization of receptors specific for human pancreatic secretory trypsin inhibitor. J Exp Med. 1990;172:1133–42.CrossRefPubMed Niinobu T et al. Identification and characterization of receptors specific for human pancreatic secretory trypsin inhibitor. J Exp Med. 1990;172:1133–42.CrossRefPubMed
22.
go back to reference Ohmuraya M, Yamamura K. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. Exp Anim. 2011;60(5):433–44.CrossRefPubMed Ohmuraya M, Yamamura K. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. Exp Anim. 2011;60(5):433–44.CrossRefPubMed
Metadata
Title
The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line
Authors
Jing Zhang
Dongmei Wang
Na Hu
Qian Wang
Shanice Yu
Jun Wang
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4405-z

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine